NCT07084961View on ClinicalTrials.gov

A Pharmacodynamic Study of TS-172 in Healthy Adult Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 5, 2025

Primary Completion Date

September 11, 2025

Study Completion Date

September 16, 2025

Conditions
Healthy Adult Male Subjects
Interventions
DRUG

TS-172

Oral administration of TS-172 20 mg immediately before meal

DRUG

TS-172

Oral administration of TS-172 20 mg immediately after meal

Trial Locations (1)

Unknown

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY